NVS maintains strong momentum on the back of a strong and diverse portfolio with drugs like Entresto, Kesimpta, Kisqali, Cosentyx, Pluvicto and Leqvio. With the separation of Sandoz, Novartis is ...

Immunocompromised people and those who are age 65 or older should get a second dose of the 2024-2025 COVID-19 vaccine, according to the latest recommendations from the Centers for Disease Control ...

Low dose birth control pills may have fewer side effects compared with older, higher-dose ones, but certain groups may still have increased health risks. If they aren’t taken correctly ...

The correct dosage of glutamine varies from person to person and what you are taking it for. If you are using an over-the-counter supplement, refer to the dosage guide on the label or ask your doctor.

In its latest guidance, released Wednesday, the CDC recommends that adults aged 65 and older, as well as individuals with weakened immune systems, receive a second dose of the updated vaccine six ...

Immunocompromised adults or those who are older than 65 should get a second dose of the latest COVID-19 vaccine, the Centers for Disease Control and Prevention (CDC) officially recommended.

Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...

The National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for breast cancer, providing a boost to Novartis' (NOVN: VX) Kisqali (ribociclib). The new guidelines make ...

Novartis’ revenues in the third quarter of 2024 are likely to have been driven by key drugs like Kesimpta, Entresto, Kisqali, Cosentyx and Pluvicto. New York-based Pfizer has an Earnings ESP of ...

Iodine is an important mineral found in nature, especially in oceans. Your body needs iodine to function properly. But it can't make it on its own. Instead, you need to get enough iodine through ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

Data from the pivotal trial also showed that Kisqali's safety profile at the 400mg dose was well-tolerated, with generally low-grade symptomatic adverse events. Following the CHMP’s positive ...